|
Contents |
|
|
|
|
|
|
Anaplastic
Astrocytomas
|
 
|
|
|
|
Sadones J, Michotte A, Veld P, Chaskis C, Sciot
R, Menten J, Joossens EJ, Strauven T, D'Hondt LA, Sartenaer D, Califice SF,
Bierau K, Svensson C, De Grève J, Neyns B.
MGMT promoter hypermethylation correlates with a survival benefit from
temozolomide in patients with recurrent anaplastic astrocytoma but not
glioblastoma
Eur J Cancer. 2008 Oct 20; [Epub ahead of print]
.JPG)
Abstract
|
|
|
Cancer
Research
|
|
|
|
Dolan ME, Pegg AE
O6-benzylguanine
and its role in chemotherapy
Clin Cancer Res
1997 Jun;3(6):837-47
|
|
Pegg
AE
Mammalian
O6-alkylguanine-DNA alkyltransferase: regulation and importance in
response to alkylating carcinogenic and therapeutic agents
Cancer Res 1990 Oct 1;50(19):6119-29
|
|
Pourquier
P, Waltman JL, Urasaki Y, Loktionova NA, Pegg AE, Nitiss JL,
Pommier Y
Topoisomerase
I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of
topoisomerase I by the O6-methylguanine
Cancer
Res 2001 Jan 1;61(1):53-8 (PDF Full Text)
|
|
|
Choroid
Plexus Tumors
|
|
|
|
|
Hasselblatt
M, Mühlisch J, Wrede B, Kallinger B, Jeibmann A, Peters O, Kutluk T, Wolff
JE, Paulus W, Frühwald MC
Aberrant
MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation in
choroid plexus tumors
J Neurooncol.
2009 Jan;91(2):151-5. Epub 2008 Sep 16
Abstract
|
|
|
Glioblastoma
|
|
|
|
Balana C,
Ramirez JL, Taron M, Roussos Y, Ariza A, Ballester R, Sarries C, Mendez P,
Sanchez JJ, Rosell R
O(6)-methyl-guanine-DNA
methyltransferase Methylation in Serum and Tumor DNA Predicts Response to
1,3-Bis(2-Chloroethyl)-1-Nitrosourea but not to Temozolamide Plus
Cisplatin in Glioblastoma Multiforme
Clin Cancer Res
2003 Apr;9(4):1461-8
|
|
Benyahia B, Huguet S, Decleves X, Mokhtari K, Criniere E, Bernaudin JF,
Scherrmann JM, Delattre JY
Multidrug resistance-associated protein MRP1 expression in
human gliomas: chemosensitization to vincristine and etoposide by indomethacin
in human glioma cell lines overexpressing MRP1
J Neurooncol. 2004 Jan;66(1-2):65-70. (Abstract+)
|
|
Lorena Bissola, Marica Eoli, Francesca Menghi, Bianca Pollo, Antonio
Silvani, Giovanni Broggi, Amerigo Boiardi, Gaetano Finocchiaro
MGMT promoter hypermethylation is more frequent in secondary
glioblastomas and is independent from other prognostic factors
Proceedings of the AACR, Volume 45, March 2004. Abstract
Number: 1077
|
|
|
Bleau AM, Huse JT, Holland EC
The ABCG2 resistance network of glioblastoma
Cell Cycle. 2009 Sep 15;8(18):2936-44
Abstract
|
|
|
Brandes
AA, Franceschi E, Tosoni A, Bartolini S, Bacci A, Agati R, Ghimenton C,
Turazzi S, Talacchi A, Skrap M, Marucci G, Volpin L, Morandi L, Pizzolitto
S, Gardiman M, Andreoli A, Calbucci F, Ermani M
O(6)-methylguanine DNA-methyltransferase methylation status can change
between first surgery for newly diagnosed glioblastoma and second surgery
for recurrence: clinical implications
Neuro Oncol. 2010 Mar;12(3):283-8
Abstract
|
|
Alba
Ariela Brandes, Mario Ermani, Umberto Basso, Lara Maria Pasetto, Francesca
Vastola, Franco Berti, Silvia Berlucchi, Pietro Amistà, Antonello Rotilio,
Silvio Monfardini
Procarbazine
Prior to and Concomitant with BCNU in Patients with Glioblastoma at First
Relapse: a Phase II Study
ASCO
Proceedings, 2001 Annual Meeting, Abstract
|
|
|
Carlson CNO, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ,
Decker PA, Giannini C, Wu W, Ballman KA, James CD, Sarkaria JN
Radiosensitizing effects of temozolomide observed in vivo only in a
subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma
multiforme xenografts
Int
J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):212-9
Abstract
|
|
|
Costa BM, Caeiro C, Guimarães I, Martinho O, Jaraquemada T, Augusto I, Castro L,
Osório L, Linhares P, Honavar M, Resende M, Braga F, Silva A, Pardal F,
Amorim J, Nabiço R, Almeida R, Alegria C, Pires M, Pinheiro C, Carvalho E,
Lopes JM, Costa P, Damasceno M, Reis RM.
Prognostic value of MGMT promoter methylation in glioblastoma patients
treated with temozolomide-based chemoradiation: a Portuguese multicentre
study
Oncol Rep. 2010 Jun;23(6):1655-62
Abstract
|
|
|
Della Puppa A, Persano L, Masi G, Rampazzo E, Sinigaglia A, Pistollato F,
Denaro L, Barzon L, Palù G, Basso G, Scienza R, d'Avella D.
MGMT
expression and promoter methylation status may depend on the site of
surgical sample collection within glioblastoma: a possible pitfall in
stratification of patients?
J Neurooncol.
2011 Jul 2. [Epub ahead of print]
Abstract |
.gif) Related articles
|
|
|
Dunn J, Baborie A, Alam F, Joyce K, Moxham M,
Sibson R, Crooks D, Husband D, Shenoy A, Brodbelt A, Wong H, Liloglou T,
Haylock B, Walker C
Extent
of MGMT promoter methylation correlates with outcome in glioblastomas given
temozolomide and radiotherapy
Br J Cancer.
2009 Jul 7;101(1):124-31. Epub 2009 Jun 16
Abstract
|
|
Durmaz R,
Deliorman S, Uyar R, Isiksoy S, Erol K, Tel E
The
effects of anticancer drugs in combination with nimodipine and verapamil on
cultured cells of glioblastoma multiforme
Clin Neurol Neurosurg. 1999 Dec;101(4):238-44
|
|
|
Franceschi E, Tosoni A, Pozzati E, Brandes AA
Association between response to primary treatments and MGMT status in
glioblastoma
Expert Rev Anticancer Ther. 2008 Nov;8(11):1781-6
Abstract
|
|
|
Goellner EM, Grimme B, Brown AR, Lin YC, Wang XH, Sugrue KF, Mitchell L, Trivedi RN,
Tang JB, Sobol RW.
Overcoming Temozolomide Resistance in Glioblastoma via Dual Inhibition of
NAD+ Biosynthesis and Base Excision Repair.
Cancer Res. 2011 Mar 15;71(6):2308-17.
Abstract |
Related articles
|
|
|
Hegi ME, Liu L, Herman JG, Stupp R, Wick W,
Weller M, Mehta MP, Gilbert MR
Correlation of O6-methylguanine methyltransferase (MGMT) promoter
methylation with clinical outcomes in glioblastoma and clinical strategies
to modulate MGMT activity
J Clin Oncol. 2008 Sep 1;26(25):4189-99
Abstract
|
|
|
Kitange GJ, Carlson CNO, Mladek AC, Decker PA, Schroeder MA, Wu W, Grogan PT,
Giannini C, Ballman KV, Buckner JC, David James C, Sarkaria JN
Evaluation
of MGMT promoter methylation status and correlation with temozolomide
response in orthotopic glioblastoma xenograft model
J Neurooncol.
2008 Nov 15. [Epub ahead of print]
Abstract
|
|
|
Kitange
GJ, Carlson CNO, Schroeder MA, Grogan PT, Lamont JD, Decker PA, Wu W, James
CD, Sarkaria JN
Induction of MGMT expression is associated with temozolomide resistance
in glioblastoma xenografts
Neuro Oncol. 2008 Nov 3; [Epub ahead of print] First
published on October 24, 2008
Abstract
|
|
|
Koch D, Hundsberger T, Boor S, Kaina B.
Local intracerebral administration of O6-benzylguanine combined
with systemic chemotherapy with temozolomide of a patient suffering from a
recurrent glioblastoma
J Neurooncol. 2006 Sep 20; [Epub
ahead of print]
Abstract
|
|
|
Li S, Zhang W, Chen B, Jiang T, Wang Z
Prognostic and predictive value of p53 in low MGMT expressing
glioblastoma treated with surgery, radiation and adjuvant temozolomide
chemotherapy
Neurol Res.
2009 Aug 21. [Epub ahead of print]
Abstract
|
|
|
Löw S, Vougioukas VI, Hielscher T, Schmidt U, Unterberg A, Halatsch
ME
Pathogenetic pathways leading to glioblastoma multiforme: association
between gene expressions and resistance to erlotinib
Anticancer Res. 2008 Nov-Dec;28(6A):3729-32
Abstract
|
|
|
Maxwell JA, Johnson SP, McLendon RE, Lister DW,
Horne KS, Rasheed A, Quinn JA, Ali-Osman F, Friedman AH, Modrich PL, Bigner
DD, Friedman HS.
Mismatch repair deficiency does not mediate clinical resistance to
temozolomide in malignant glioma
Clin Cancer Res. 2008 Aug 1;14(15):4859-68
Abstract
|
|
|
Mellai M, Caldera V, Annovazzi L, Chiò
A, Lanotte M, Cassoni P, Finocchiaro G, Schiffer D
MGMT Promoter Hypermethylation in a Series of 104 Glioblastomas
Cancer Genomics Proteomics. 2009 Jul-Aug;6(4):219-27
Abstract
|
|
|
Park CK, Park SH, Lee SH, Kim CY, Kim DW, Paek SH, Kim DG, Heo DS, Kim IH, Jung
HW
Methylation status of the MGMT gene promoter fails to predict the clinical
outcome of glioblastoma patients treated with ACNU plus cisplatin
Neuropathology. 2009 Jan 6. [Epub ahead of print]
Abstract | .png)
Full Text | .png)
Reprint
|
|
|
Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, Cook RJ,
Messina M, Robinson BG, McDonald KL.
Variation of O(6)-methylguanine-DNA methyltransferase
(MGMT) promoter methylation in serial samples in glioblastoma.
J Neurooncol.
2007 Nov 15; [Epub ahead of print]
Abstract
|
|
|
Preusser
M, Janzer RC, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R,
Gorlia T, Marosi C, Heinzl H, Hainfellner JA, Hegi M
Anti-O6-Methylguanine-Methyltransferase (MGMT) Immunohistochemistry in
Glioblastoma Multiforme: Observer Variability and Lack of Association with
Patient Survival Impede Its Use as Clinical Biomarker
Brain Pathol. 2008 Apr 8;. [Epub ahead of print]
Abstract
|
|
Meg Verrees, Lili Liu, Stanton L. Gerson
Interruption of base excision repair selectively enhances
temozolamide and 1,3-bis(2-chloroethyl)-nitrosurea cytotoxicity in treatment of
adult human malignant glioma cell lines
Proceedings of the AACR, Volume 45, March 2004, Abstract
Number: 1548.
|
|
|
Watson
AJ, Sabharwal A, Thorncroft M, McGown G, Kerr R, Bojanic S, Soonawalla Z,
King A, Miller A, Waller S, Leung H, Margison GP, Middleton MR
Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral
lomeguatrib
Clin Cancer Res. 2010 Jan 15;16(2):743-9. Epub 2010 Jan 12
Abstract
|
|
|
Weller
M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME.
MGMT promoter methylation in malignant gliomas: ready for personalized
medicine?
Nat Rev Neurol. 2009 Dec 8;. [Epub ahead of print]
Abstract
|
|
Elderly
patients
|
|
|
|
Minniti
G, Salvati M, Arcella A, Buttarelli F, D'Elia A, Lanzetta G, Esposito V,
Scarpino S, Maurizi Enrici R, Giangaspero F
Correlation
between O(6)-methylguanine-DNA methyltransferase and survival in elderly
patients with glioblastoma treated with radiotherapy plus concomitant and
adjuvant temozolomide
J
Neurooncol. 2010 Aug 5. [Epub ahead of print]
Abstract
|
|
|
Gliomas
|
|
|
|
Beith
J., Cook R., Robinson B., Levi J., Bell D., Wheeler H.
Modulation of resistance to BCNU by depleting
MGMT activity with procarbazine in patients with relapsed high-grade
gliomas
ASCO
Proceedings, 1997 Annual Meeting, Abstract No. 1375
|
|
|
Dora
B. Bocangel, Sydney Finkelstein, S. Clifford Schold, Kishor K. Bhakat, Sankar
Mitra and Demetrius M. Kokkinakis
Multifaceted Resistance of Gliomas to Temozolomide
Clinical Cancer Research Vol. 8, 2725-2734, 1 August 2002
Abstract |
Full Text |
Reprint
|
|
T.
Burton, P. Baijal, E. Henson, S. Zhang, S.B. Gibson, and D.D. Eisenstat
The Hypoxia-Inducible Cell Death Gene
BNIP3 In Malignant Gliomas
Society
for Neuro-Oncology Eighth Annual Meeting. Keystone, Colorado. November 13–16,
2003. Abstract No. AN-05.
Neuro-Oncology, Volume 5, CNO 4, October 2003
|
|
S.
M. Chang, W. K. A. Yung, J. Kuhn, D. Schiff, H. Fine, M. Mehta, I.
Robins, L. Junck, K. Hess, M. Prados
Phase II study of
neoadjuvant BCNU and temozolomide for newly diagnosed anaplastic glioma
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
413
|
|
Francis Ali-Osman,
Olanike Akande, Gamil Antoun, and Henry Friedman
Transcriptional activitation of the GSTP1
gene by wind-type p53 results in a DNA-mismatch-repair–dependent NER: a
novel p53-GSTP1 mediated mechanism of alkylator resistance in human
gliomas
15th International Conference on Brain Tumor Research and Therapy.
Sorrento, Italy. May 24–27, 2003. Abstract No. 2
Neuro-Oncology, Volume 5, CNO 4, October 2003
|
|
Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC,
Bigner DD, Dolan ME
O6-benzylguanine-mediated
enhancement of chemotherapy
Mol Cancer Ther 2002
Sep;1(11):943-8
|
|
Henry
S Friedman, James Pluda, Jon Weingart, Henry Brem, Brandon Evans, William
Petros, Jeremy Rich, Sandra Tourt-Uhlig, Sridharan Gururangan, David Reardon,
John Sampson, Allan Friedman, James Provenzale, Roger McLendon, O. M Colvin,
Darell D Bigner, M. E Dolan, Anthony Pegg, Robert Moschel, Jennifer Quinn
Phase I trial of temodar plus O6-benzylguanine
in the treatment of patients with recurrent or progressive cerebral anaplastic
gliomas
ASCO
Proceedings, 2002 Annual Meeting, Abstract No.
311
|
|
Friedman HS,
McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J,
Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin
OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL
DNA
mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response
to Temodal in newly diagnosed malignant glioma
J Clin Oncol 1998 Dec;16(12):3851-7
|
|
Gander
M, Leyvraz S, Decosterd L, Bonfanti M, Marzolini C, Shen F, Lienard D,
Perey L, Colella G, Biollaz J, Lejeune F, Yarosh D, Belanich M, D'Incalci
M.
Sequential administration of temozolomide and
fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood
lymphocytes and in tumours.
Ann Oncol 1999 Jul;10(7):831-8
Abstract |
Reprint |
Related articles
|
|
Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich
M, Yarosh DB, Bearman SI, Giroux DJ, Schold SC
Correlation
of tumor O6 methylguanine-DNA methyltransferase levels with survival of
malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a
Southwest Oncology Group study
J Clin Oncol 1998
Oct;16(10):3310-5
|
|
Takao Kanzawa, Hideaki Ito, Yasuko Kondo, Seiji Kondo
Role of autophagy in temozolomide-induced cytotoxicity for
malignant glioma cells
Proceedings of the AACR, Volume 45, March 2004, Abstract
Number: 579.
|
|
Kanzawa T,
Germano IM, Kondo Y, Ito H, Kyo S, Kondo S
Inhibition
of telomerase activity in malignant glioma cells correlates with their
sensitivity to temozolomide
Br J Cancer.
2003 Sep 1;89(5):922-929
|
|
Satoshi
Nakasu, Tadateru Fukami, Kazumi Baba, Masayuki Matsuda
Immunohistochemical
study for O6-methylguanine-DNA methyltransferase in the
non-neoplastic and neoplastic components of gliomas
Journal
of Neuro-Oncology, 70(3):
333-340, December 2004. (Abstract+)
|
|
Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L,
Garcia-Lopez JL, Piquer J, Safont MJ, Balana C, Sanchez-Cespedes M,
Garcia-Villanueva M, Arribas L, Esteller M
CpG island hypermethylation of the DNA repair enzyme
methyltransferase predicts response to temozolomide in primary gliomas
Clin Cancer Res. 2004 Aug 1;10(15):4933-8.
|
|
Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T
A prospective blinded study of the predictive value of
an extreme drug resistance assay in patients receiving CPT-11 for recurrent
glioma
J Neurooncol. 2004 Feb;66(3):365-75. (Abstract+)
|
|
J.
A. Quinn, J. Weingart, H. Brem, J. Rich, D. Reardon, J. Sampson, A.
Friedman, H. S. Friedman, O. M. Colvin, E. Dolan
Phase I trial
of temozolomide plus O6-benzylguanine in the treatment of
patients with recurrent or progressive cerebral anaplastic gliomas
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
411
|
|
Jennifer
A. Quinn, M. Eileen Dolan, Anthony E. Pegg, Robert C. Moschel, James Pluda,
Roger E. McLendon, James Provenzale, William Petros, Sandra Tourt-Uhlig, Jeremy
N. Rich, Sridharan Gururangan, Mary L. Affronti, Waynette Buchanan, O. Michael
Colvin, Elizabeth S. Stewart, Allan H. Friedman, Darell D. Bigner, Henry S.
Friedman
Phase II Trial of BCNU Plus O6-Benzylguanine
for Patients with Recurrent or Progressive Malignant Glioma
ASCO
Proceedings, 2001 Annual Meeting, Abstract
No.251
|
|
S.
N. Raval, B. Gu, J. J. Raizer, M. K. Rosenblum, D. Banerjee, J. R.
Bertino, L. M. DeAngelis
Methylation of MGMT promotor, the DNA repair gene
as an independent prognostic factor for malignant glioma
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
452
|
|
Mark
Rosenblum, J Weingart, Eileen Dolan, S Tatter, K Judy, J Olson, E Bohan, J
Fisher
Phase
I study of Gliadel combined with a continuous intravenous infusion of
O6-benzylguanine in patients with recurrent malignant glioma
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No.
314
|
|
|
Sarkaria
JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W
Mechanisms of chemoresistance to alkylating agents in malignant glioma
Clin
Cancer Res. 2008 May 15;14(10):2900-8
Abstract
|
|
S. Clifford Schold Jr., Demetrius M. Kokkinakis,
Susan M. Chang, Mitchel S. Berger, Kenneth R. Hess, David Schiff, H. Ian
Robins, Minesh P. Mehta, Karen L. Fink, R.L. Davis, and Michael D. Prados
O6-Benzylguanine
suppression of O6-alkylguanine-DNA alkyltransferase in
anaplastic gliomas
Neuro-Oncology,
January 2004, Volume 6 Number 1, Pages 28 -- 32
|
|
Antonio
Silvani, Marica Eoli, Andrea Salmaggi, Elena Lamperti, Elio
Maccagnano, Giovanni Broggi, Amerigo Boiardi
Phase
II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive
Malignant Glioma Patients
Journal of Neuro-Oncology, 66 (1-2): 203-208, January 2004
|
|
Slancar
M., Wheeler H., Cook R., Levi J., Bell D., Beith J.
Increased pulmonary toxicity with scheduling
procarbazine prior to BCNU in patients with high-grade gliomas
ASCO
Proceedings, 1997 Annual Meeting, Abstract No. 1459
|
|
|
Vlassenbroeck I, Califice S, Diserens AC,
Migliavacca E, Straub J, Di Stefano I, Moreau F, Hamou MF, Renard I,
Delorenzi M, Flamion B, Diguiseppi J, Bierau K, Hegi ME
Validation of Real-Time Methylation-Specific PCR to Determine
O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma
J Mol Diagn. 2008 Jul;10(4):332-337. Epub 2008 Jun 13
Abstract
|
|
|
Gliomas
(High-Grade)
|
|
|
|
|
Pan Q, Yang XJ, Wang HM, Dong XT, Wang W, Li Y, Li
JM.
Chemoresistance to Temozolomide in Human Glioma
Cell Line U251 is Associated with Increased Activity of O
(6)-methylguanine-DNA
Methyltransferase and Can be Overcome by Metronomic Temozolomide Regimen.
Cell Biochem Biophys. 2011 Sep 4;. [Epub ahead of
print]
Abstract |
Related articles°
|
|
|
Rahman
R, Smith S, Rahman C, Grundy R.
Antiangiogenic therapy and mechanisms of tumor resistance in malignant
glioma
J Oncol. 2010;2010:251231. Published online
2010 April 11
Abstract |
Full Text |
Reprint
|
|
|
Suri V, Jha P, Sharma MC, Sarkar C.
O 6 -methylguanine DNA methyltransferase gene promoter
methylation in high-grade gliomas: A review of current status
Neurol India, 2011 March-April, Volume 59 Issue 2, 59:229-235
Abstract |
Full
text
|
|
|
Tanaka S, Akimoto J, Kobayashi I, Oka H, Ujiie H
Individual adjuvant therapy for malignant gliomas based on
O6-methylguanine-DNA methyltransferase messenger RNA quantitation by
real-time reverse-transcription polymerase chain-reaction
Oncol Rep. 2008 Jul;20(1):165-71
Abstract
|
|
|
Yang
SH, Kim YH, Kim JW, Park CK, Park SH, Jung HW
Methylation Status of the O6-Methylguanine-Deoxyribonucleic Acid
Methyltransferase Gene Promoter in World Health Organization Grade III
Gliomas
J Korean Neurosurg Soc. 2009 Oct;46(4):385-8
Abstract |
Full Text |
Reprint
|
|
|
Malignant Lymphoma
|
|
|
|
B.
Evans, J. Quinn, D. Reardon, J. Rich, S. Gururangan, A. Friedman, R.
McLendon, S. Tourt-Uhlig, V. Stafford-Fox, H. S. Friedman
Phase II
treatment of adults with newly diagnosed, progressive or recurrent primary
central nervous system lymphoma with temozolomide
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
438
|
|
|
Kurzwelly
D, Glas M, Roth P, Weimann E, Lohner H, Waha A, Schabet M, Reifenberger G,
Weller M, Herrlinger U
Primary
CNS lymphoma in the elderly: temozolomide therapy and MGMT status
J
Neurooncol. 2010 May;97(3):389-92. Epub 2009 Oct 20
Abstract |
Full Text |
Reprint
|
|
|
Medulloblastoma |
|
|
|
Demetrius M. Kokkinakis, Robert C.
Moschel, Anthony E. Pegg and S. Clifford Schold
Eradication of Human
Medulloblastoma Tumor Xenografts with a Combination of O6-Benzyl-2'-deoxyguanosine
and 1,3-Bis(2-chloroethyl)-1-nitrosourea
Clinical Cancer Research Vol. 5, 3676-3681, November 1, 1999. (PDF Full Text)
|
|
|
Meningioma |
|
|
|
|
de
Robles P, McIntyre J, Kalra S, Roldán G, Cairncross G, Forsyth P, Magliocco
T, Hamilton M, Easaw J
Methylation status of MGMT gene promoter in
meningiomas
Cancer
Genet Cytogenet. 2008 Nov;187(1):25-7
Abstract
|
|
|
Metastatic Tumors
|
|
|
|
Lucio Tentori, Carlo Leonetti, Marco Scarsella, Weizheng Xu,
David C. Calvin, Lisa Morgan, Zhaocheng Tang, Krystyna M. Wozniak, Christina
Alemu, Randall Hoover, Rena G. Lapidus, Gabriella Zupi, Jie Zhang, Grazia
Graziani
Oral administration of the PARP-1 inhibitor GPI 15427 increases
the anti-tumor activity of temozolomide against melanoma growing at the CNS site
Proceedings of the AACR, Volume 45, March 2004, Abstract
Number: 2007.
|
|
|
Non-CNS Tumors
|
|
|
|
D'Atri S, Tentori L, Lacal PM,
Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E, Jiricny J
Involvement
of the mismatch repair system in temozolomide-induced apoptosis
Mol Pharmacol 1998 Aug;54(2):334-41
|
|
|
Pediatric
Patients |
|
|
|
Michael S.
Bobola, Richard Ellenbogen, Ryan Goff, John Silber
Ablation of O6-methylguanine-DNA methyltransferase
with O6-benzylguanine reduces the resistance of pediatric primary
brain tumor cell lines to temozolomide and BCNU
Proceedings of the AACR, Volume 45, March 2004, Abstract
Number: 2143.
|
|
|
Broniscer A, Gururangan S, Macdonald TJ, Goldman
S, Packer RJ, Stewart CF, Wallace D, Danks MK, Friedman HS, Poussaint TY,
Kun LE, Boyett JM, Gajjar A; for the Pediatric Brain Tumor Consortium.
Phase I Trial of Single-Dose Temozolomide and Continuous Administration
of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor
Consortium Report
Clin
Cancer Res. 2007 Nov 15;13(22):6712-6718
Abstract
|
|
|
Lee JY, Park CK, Park SH, Wang KC, Cho BK, Kim SK.
MGMT promoter gene methylation in pediatric glioblastoma: analysis using
MS-MLPA.
Childs
Nerv Syst. 2011 Jul 26. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Sardi I, Cetica V, Massimino M, Buccoliero AM,
Giunti L, Genitori L, Aricò M
Promoter methylation and expression analysis of MGMT in advanced
pediatric brain tumors
Oncol Rep. 2009 Oct;22(4):773-9
Abstract
|
bottom
|
